

HemoShear Therapeutics to Present at Piper Sandler Annual Healthcare Conference

HemoShear Therapeutics, LLC, a privately held clinical stage company developing treatments for rare metabolic disorders, has been invited to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference, to be held from November 30 through December 2, 2020. HemoShear's presentation has been pre-recorded for advance viewing by attendees.

"HemoShear is preparing to initiate its phase 2 study of HST5040 in patients with methylmalonic and propionic acidemia early in 2021," said Jim Powers, Chairman and CEO. "We look forward to sharing details of our progress with the investment community."

Click [here](#) to view the pre-recorded presentation.

HemoShear has received clearance from the FDA to conduct a phase 2 clinical study of its oral drug HST5040 in patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). MMA and PA are rare genetic disorders caused by the deficiency of certain enzymes required to metabolize amino acids. The diseases result in the rapid buildup of life-threatening metabolites that can lead to severe organ damage, seizures, developmental deficits, and premature death. HemoShear's phase 2 clinical study, HERO (HElp Reduce Organic Acids), is designed to enroll at least 12 patients with MMA and PA at select children's hospitals in the United States.